Neutralizing antibodies (NAb) have been identified as key molecules for the treatment, prevention and research of COVID-19 disease. However, due to the need to evaluate the neutralization performance of many candidates at an early stage, the development of NAb against pathogens can be a complicated process. Traditional methods of measuring virus neutralization include the use of the time-consuming virus neutralization test (VNT), pseudovirus neutralization test (pVNT), or table reduction neutralization test (PRNT), which requires also the use of facilities with strict pathogenic toxicity. (biosafety level 3). Regarding SAV-CoV-2 (the causative agent of COVID-19 disease), NAb is defined as the interaction between the virus-blocking spike protein (specifically its receptor binding domain (RBD)) and the Ability virus. Specific receptor on the surface of human cells (ACE2). Anti-CoV-RBD (G1) antibodies belong to a unique class of antibodies with neutralizing activity. Recombinant forms of RBD have been used as target antigens to be isolated from the highly diverse human COVID-19 antibody library (LiAb-SFCOVID-19 ™). Additionally, the candidate neutralizing activity is predicted by our SARS-CoV-2 Alternative Virus Neutralization Test (sVNT), which detects antibodies that can effectively compete with ACE2 for the RBD binding pouch. Furthermore, the stability and ease of production of the antibody were verified by producing milligrams in the transient system of mammalian XtenCHO.
The antibody can be used as an effective reaction reagent to study the progression of COVID-19 disease and can be used as a monitoring tool to determine the long and short-term immune development of SARS-CoV-2 in the world population.
Anti-RBD-1 (Etesevimab) antibody, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized RBD Domain (cat. No.PX-COV-P046) at 0.5µg/mL (100µL/well) can bind to Anti-RBD-1 (Etesevimab) antibody (cat. No.PTXCOV-A549) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
– March 11, 2022
This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody showed expected neutralization of wild type, Alpha, Gamma, and Delta variants (IC50 24.23 ng/mL for the wild type, 86.18 ng/mL for Alpha, >500 ng/mL for Gamma and 8.44 ng/ml for Delta).
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Got a question or need a quote? Message us and we’ll get back to you 48 hours or less.
Lab / Company